Merit Cudkowicz
Executive Director, Neurosciences Institute · Mass General Brigham
Credentials: · · · ·
History
- Present
Neurosciences Institute Center · Mass General Brigham
- 1995–1996
- 1986–1990
Research
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
New England Journal of Medicine · 2022 · 755 citations
Movement Disorders · 1998 · 601 citations
Genome-wide Analyses Identify KIF5A as a Novel ALS Gene
Neuron · 2018 · 571 citations
72 papers · 1 as a fellow
67 papers
54 papers · 6 as a fellow
41 papers · 8 as a resident
- NA
35 papers
27 papers
24 papers · 1 as a fellow
24 papers
Grants
- 2011–2028
National Institute of Neurological Disorders and Stroke · U01
Contact PI · $43.4M · Massachusetts General Hospital
- 2024–2027
Gene Therapy Consortium (GTC) for Gene-Based Clinical Trials Conducted Within NeuroNEXT
National Institute of Neurological Disorders and Stroke · OT2
Contact PI · $5.6M · Massachusetts General Hospital
- 2017–2024
Topiramate as a Disease Altering Therapy for CSPN
National Institute of Neurological Disorders and Stroke · U01
PI · $7.3M · Virginia Commonwealth University
- 2015–2019
Tolerability of SRX246 in Huntington's Disease Patients
National Institute of Neurological Disorders and Stroke · U44
PI · $5.6M · Azevan Pharmaceuticals, Inc.
Clinical trials
- 2026–2028
HEALEY ALS Platform Trial - Regimen I NUZ-001
Principal investigator · Active not recruiting · Phase 2, Phase 3
Merit E. Cudkowicz, MD
- 2023–2024
HEALEY ALS Platform Trial - Regimen G DNL343
Principal investigator · Completed · Phase 2, Phase 3
Merit E. Cudkowicz, MD
- 2023–2024
HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262
Principal investigator · Completed · Phase 2, Phase 3
Merit E. Cudkowicz, MD
- 2022–2023
HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose
Principal investigator · Completed · Phase 2, Phase 3
Merit E. Cudkowicz, MD